These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34871500)

  • 1. Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1.
    Boyd MJ; Collier PN; Clark MP; Deng H; Kesavan S; Ronkin SM; Waal N; Wang J; Cao J; Li P; Come J; Davies I; Duffy JP; Cochran JE; Court JJ; Chandupatla K; Jackson KL; Maltais F; O'Dowd H; Boucher C; Considine T; Taylor WP; Gao H; Chakilam A; Engtrakul J; Crawford D; Doyle E; Phillips J; Kemper R; Swett R; Empfield J; Bunnage ME; Charifson PS; Magavi SS
    J Med Chem; 2021 Dec; 64(24):17777-17794. PubMed ID: 34871500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1.
    Come JH; Senter TJ; Clark MP; Court JJ; Gale-Day Z; Gu W; Krueger E; Liang J; Morris M; Nanthakumar S; O'Dowd H; Maltais F; Iyer G; Andreassi J; Boucher C; Considine T; Moody CS; Taylor W; Mohanty AK; Huang Y; Zuccola H; Coll J; Bonanno KC; Gagnon KJ; Gan L; Lu F; Gao H; Chakilam A; Engtrakul J; Song B; Crawford D; Doyle E; Kramer T; Vought B; Phillips J; Kemper R; Sanders M; Swett R; Furey B; Winquist R; Bunnage ME; Jackson KL; Charifson PS; Magavi SS
    J Med Chem; 2021 Dec; 64(24):17753-17776. PubMed ID: 34748351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy.
    Ofman R; Dijkstra IM; van Roermund CW; Burger N; Turkenburg M; van Cruchten A; van Engen CE; Wanders RJ; Kemp S
    EMBO Mol Med; 2010 Mar; 2(3):90-7. PubMed ID: 20166112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation.
    Engelen M; Schackmann MJ; Ofman R; Sanders RJ; Dijkstra IM; Houten SM; Fourcade S; Pujol A; Poll-The BT; Wanders RJ; Kemp S
    J Inherit Metab Dis; 2012 Nov; 35(6):1137-45. PubMed ID: 22447153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis.
    Schackmann MJ; Ofman R; Dijkstra IM; Wanders RJ; Kemp S
    Biochim Biophys Acta; 2015 Feb; 1851(2):231-7. PubMed ID: 25499606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
    Singh J; Khan M; Singh I
    J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.
    Singh J; Khan M; Singh I
    Biochim Biophys Acta; 2013 Apr; 1831(4):747-58. PubMed ID: 23318275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery for X-linked adrenoleukodystrophy: An unbiased screen for compounds that lower very long-chain fatty acids.
    Moser AB; Liu Y; Shi X; Schrifl U; Hiebler S; Fatemi A; Braverman NE; Steinberg SJ; Watkins PA
    J Cell Biochem; 2021 Oct; 122(10):1337-1349. PubMed ID: 34056752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational insight into structural basis of human ELOVL1 inhibition.
    Siddiqui AJ; Kumar V; Jahan S; Alshahrani MM; Al Awadh AA; Siddiqui MA; Hamadou WS; Abdelgadir A; Saxena J; Badraoui R; Snoussi M; Adnan M
    Comput Biol Med; 2023 May; 157():106786. PubMed ID: 36924735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy.
    McGuinness MC; Zhang HP; Smith KD
    Mol Genet Metab; 2001; 74(1-2):256-63. PubMed ID: 11592822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents].
    Morita M
    Yakugaku Zasshi; 2007 Jul; 127(7):1059-64. PubMed ID: 17603264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions.
    Kruska N; Schönfeld P; Pujol A; Reiser G
    Biochim Biophys Acta; 2015 May; 1852(5):925-36. PubMed ID: 25583114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lorenzo's oil inhibits ELOVL1 and lowers the level of sphingomyelin with a saturated very long-chain fatty acid.
    Sassa T; Wakashima T; Ohno Y; Kihara A
    J Lipid Res; 2014 Mar; 55(3):524-30. PubMed ID: 24489110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).
    Ryu JH; Lee JA; Kim S; Shin YA; Yang J; Han HY; Son HJ; Kim YH; Sa JH; Kim JS; Lee J; Lee J; Park HG
    J Med Chem; 2016 Nov; 59(22):10176-10189. PubMed ID: 27798827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bezafibrate for X-linked adrenoleukodystrophy.
    Engelen M; Tran L; Ofman R; Brennecke J; Moser AB; Dijkstra IM; Wanders RJ; Poll-The BT; Kemp S
    PLoS One; 2012; 7(7):e41013. PubMed ID: 22911730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.
    Singh J; Olle B; Suhail H; Felicella MM; Giri S
    J Neurochem; 2016 Jul; 138(1):86-100. PubMed ID: 26849413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy.
    Fourcade S; Ruiz M; Guilera C; Hahnen E; Brichta L; Naudi A; Portero-Otín M; Dacremont G; Cartier N; Wanders R; Kemp S; Mandel JL; Wirth B; Pamplona R; Aubourg P; Pujol A
    Hum Mol Genet; 2010 May; 19(10):2005-14. PubMed ID: 20179078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
    Chen X; Xu W; Wang K; Mo M; Zhang W; Du L; Yuan X; Xu Y; Wang Y; Shen J
    J Med Chem; 2015 Nov; 58(21):8529-41. PubMed ID: 26479945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical aspects of X-linked adrenoleukodystrophy.
    Kemp S; Wanders R
    Brain Pathol; 2010 Jul; 20(4):831-7. PubMed ID: 20626744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
    Baarine M; Beeson C; Singh A; Singh I
    J Neurochem; 2015 May; 133(3):380-96. PubMed ID: 25393703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.